依诺肝素对急性冠脉综合征患者血清抵抗素浓度的影响

Influence of enoxaparin on serum resistin levels in patients with acute coronary syndrome

目的研究依诺肝素对急性冠脉综合征(acute coronary syndrome,ACS)患者血清抵抗素浓度的影响。方法选取2010年3月—2011年6月行冠状动脉造影的ACS患者93例,分为不稳定型心绞痛(unstable angina,UA)组34例、非ST段心肌梗死(non ST-segment elevation myocardial infarction,NSTEMI)组30例、ST段抬高性心肌梗死(ST-segment elevation myocardial infarction,STEMI)组29例,选择同期健康人30名作为对照组。所有患者给予依诺肝素皮下注射,收集治疗前后患者血液,经ELISA法测定血清抵抗素浓度,并进行组间比较。结果治疗后UA组、NSTEMI组、STEMI组血清抵抗素浓度分别为(8.15±1.18)、(15.21±12.03)、(15.08±2.20)μ/L,与治疗前比较,差异均有统计学意义,但仍均高于对照组(均P<0.05)。结论依诺肝素能显著降低ACS患者血清抵抗素浓度,抑制炎症反应,可减轻动脉粥样硬化。

Objective To study the influence of enoxaparin on serum resistin levels in patients with acute coronary syn- drome （ACS）. Methods From March 2010 to June 2011, a total of 93 patients with angiographically proven ACS were selected and divided into UA group （ unstable angina, 34 cases）, NSTEMI group （ non - ST - segment elevation myocardi- al infarction, 30 eases） , STEMI group （ ST - segment elevation myocardial infarction, 29 cases） and 30 healthy controls. All the groups were examined for serum resistin levels before treatment and given subcutaneous injection of enoxaparin - afterwards. Blood samples were collected before and after treatment and determined for serum resistin levels with ELISA, and comparison was carried out between groups afterwards. Results Serum resistin levels in patients with ACS [ （8.15 ±1.18 ）, （ 15.21 ±12.03 ）, （ 15.08±2.20 ） μ/L] were significantly higher than those in the healthy controls （ P 〈 0.05 ） ; enoxaparin lowered serum resistin levels in patients with ACS effectively（P 〈 0.05）. Conclusions Enoxaparin can signif- icantly decrease human serum resisdn levels, inhibit the inflammatory response and reduce atheroselerosis.